B. Riley Securities Initiates Coverage On Opus Genetics with Buy Rating, Announces Price Target of $9

Benzinga · 2d ago
B. Riley Securities analyst Mayank Mamtani initiates coverage on Opus Genetics (NASDAQ:IRD) with a Buy rating and announces Price Target of $9.